Nature Communications - Only a fraction of colorectal cancer patients responds to available therapies, for this reason a better molecular understanding of the disease in precision oncology is required. A group of scientists tested 16 clinical drugs on patient-derived in vivo and in vitro models and generated a compendium of drug sensitivity to identify novel biomarkers predicting sensitivity to the EGFR inhibitors

 

Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors

 

Authors: Moritz Schütte, Thomas Risch, NilofarAbdavi-Azar, KarstenBoehnke, Dirk Schumacher, MarlenKeil, RehaYildiriman, Christine Jandrasits, Tatiana Borodina, VyacheslavAmstislavskiy, Catherine L. Worth, Caroline Schweiger, Sandra Liebs, Martin Lange, Hans- JörgWarnatz, Lee M. Butcher, James E. Barrett, Marc Sultan, ChristophWierling, Nicole Golob-Schwarzl, Sigurd Lax, Stefan Uranitsch, Michael Becker, Yvonne Welte, Joseph Lewis Regan, Maxine Silvestrov, IngeKehler, Alberto Fusi, Thomas Kessler, Ralf Herwig, Ulf Landegren, Dirk Wienke, Mats Nilsson, Juan A. Velasco, PilarGarin-Chesa, ChristophReinhard, Stephan Beck, Reinhold Schäfer, Christian R. A. Regenbrecht, David Henderson, Bodo Lange, Johannes Haybaeck, Ulrich Keilholz, Jens Hoffmann, Hans Lehrach & Marie-Laure Yaspo

Nature Communications 8 - doi:10.1038/ncomms14262 - 10 February 2017